Growth Metrics

Enovis (ENOV) Long-Term Deferred Tax (2010 - 2011)

Enovis (ENOV) reported Long-Term Deferred Tax of $44.0 million for Q4 2011, down 16.03% year-over-year from $52.4 million in Q4 2010, and down 8.41% on a QoQ basis from $48.0 million in Q3 2011.

Enovis (ENOV) has 2 years of Long-Term Deferred Tax data on file, last reported at $44.0 million in Q4 2011.

  • Quarterly Long-Term Deferred Tax fell 16.03% year-over-year to $44.0 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $44.0 million (down 16.03% YoY) and the FY2011 annual result came in at $44.0 million, down 16.03% from the prior year.
  • Long-Term Deferred Tax eased to $44.0 million in Q4 2011 per ENOV's latest filing, from $48.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $52.4 million in Q4 2010 and bottomed at $44.0 million in Q4 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Enovis 1.25 Bn 1.22 Bn 365.49 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2011 43.99 Mn
Sep 30, 2011 48.03 Mn
Jul 1, 2011 52.12 Mn
Dec 31, 2010 52.39 Mn